May 2016 FDA Recall Drug by Attix Pharmaceuticals Inc
D-1047-2016 - cGMP deviation; manufacturer is Not Registered with the Food and Drug Administration
This Class III drug recall was voluntarily initiated by Attix Pharmaceuticals Inc on May 18, 2016 for the product Drug. The FDA reported the reason for recall as cgmp deviation; manufacturer is not registered with the food and drug administration. The product was distributed in CO and the recall is currently terminated.
Recall Number: D-1047-2016
cGMP deviation; manufacturer is Not Registered with the Food and Drug Administration
05-18-2016
06-29-2016
N/A
Recall Profile & Regulatory Data
Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Attix Pharmaceuticals Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
CO
07-26-2016
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Mycophenolate Mofetil, Bulk Powder, Quantity 1000 g, For prescription compounding use and medical manufacturing or processing only, Attix Pharmaceuticals, Toronto, Canada
Batch or Lot Expiration Information
Lot# Lot Number: A3160A, Manufacturer batch number: 151201, Expiry November 2017